1. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet 2021;398:535–54.
2. Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta 2015;1856:189–210.
3. Wadowska K, Bil-Lula I, Trembecki L, Sliwinska-Mosson M. Genetic markers in lung cancer diagnosis: a review. Int J Mol Sci 2020;21:4569.
4. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007;75:56–63. 
5. Ma Z, Fan Y, Wu Y, Kebebe D, Zhang B, Lu P, et al. Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment. Int J Nanomedicine 2019;14:2029–53.
6. Wang LH, Wu CF, Rajasekaran N, Shin YK. Loss of tumor suppressor gene function in human cancer: an overview. Cell Physiol Biochem 2018;51:2647–93.
7. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007;45:957–67.
8. Fan Y, Ma Z, Zhao L, Wang W, Gao M, Jia X, et al. Anti-tumor activities and mechanisms of Traditional Chinese medicines
formulas: A review. Biomed Pharmacother 2020;132:110820.
9. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy--from TCM theory to mechanistic insights. Planta Med 2010;76:1118–31.
10. Pan X, Tao H, Nie M, Liu Y, Huang P, Liu S, et al. A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail. Medicine (Baltimore) 2020;99:e19757.
11. Wang K, Chen Q, Shao Y, Yin S, Liu C, Liu Y, et al. Anticancer activities of TCM and their active components against tumor metastasis. Biomed Pharmacother 2021;133:111044.
12. Ling CQ, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. Journal of Integrative Medicine 2014;12:331–5. 
13. Yan Z, Lai Z, Lin J. Anticancer properties of traditional Chinese medicine. Comb Chem High Throughput Screen 2017;20:423–9.
14. Konkimalla VB, Efferth T. Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol 2008;116:207–10.
15. Liu J, Mao JJ, Wang XS, Lin H. Evaluation of traditional Chinese medicine herbs in oncology clinical trials. Cancer J 2019;25:367–71.
16. Li P, Lu Q, Jiang W, Pei X, Sun Y, Hao H, et al. Pharmacokinetics and pharmacodynamics of rhubarb anthraquinones extract in
normal and disease rats. Biomed Pharmacother 2017;91:425– 35.
17. Su J, Yan Y, Qu J, Xue X, Liu Z, Cai H. Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF- κB pathway. Oncol Rep 2017;37:1565–72.
18. Wang Y, Luo Q, He X, Wei H, Wang T, Shao J, et al. Emodin induces apoptosis of colon cancer cells via induction of autophagy in a ROS-dependent manner. Oncol Res 2018;26:889–99.
19. Manimaran A, Manoharan S, Neelakandan M. Emodin Efficacy on the Akt, Mapk, Erk, Dnmt expression pattern during Dmbainduced oral carcinoma in golden syrian hamsters. Afr J Tradit Complement Altern Med 2016;13:186–93.
20. Haque E, Kamil M, Irfan S, Sheikh S, Hasan A, Nazir A, et al. Blocking mutation independent p53 aggregation by emodin modulates autophagic cell death pathway in lung cancer. Int J Biochem Cell Biol 2018;96:90–5.
21. Semwal RB, Semwal DK, Combrinck S, Viljoen A. Emodin - A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry 2021;190:112854. 
22. Cui Y, Lu P, Song G, Liu Q, Zhu D, Liu X. Involvement of PI3K/ Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis. Food Chem Toxicol 2016;92:26–37.
23. Zhang L, He D, Li K, Liu H, Wang B, Zheng L, et al. Emodin targets mitochondrial cyclophilin D to induce apoptosis in HepG2 cells. Biomed Pharmacother 2017;90:222–8.
24. Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, et al. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett 2013;341:139–49.
25. Monisha BA, Kumar N, Tiku AB. Emodin and its role in chronic diseases. Adv Exp Med Biol 2016;928:47–73 26. Zheng Q, Li S, Li X, Liu R. Advances in the study of emodin: an update on pharmacological properties and mechanistic basis. Chin Med 2021;16:102.
27. Deyell M, Garris CS, Laughney AM. Cancer metastasis as a nonhealing wound. Br J Cancer 2021;124:1491–502.
28. Barillari G, Bei R, Manzari V, Modesti A. Infection by high-risk human papillomaviruses, epithelial-to-mesenchymal transition and squamous pre-malignant or malignant lesions of the uterine cervix: a series of chained events? Int J Mol Sci 2021;22:13543.
29. Okada F, Izutsu R, Goto K, Osaki M. Inflammation-related carcinogenesis: lessons from animal models to clinical aspects. Cancers (Basel) 2021;13:921.
30. Manjili SH, Isbell M, Ghochaghi N, Perkinson T, Manjili MH. Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. Semin Cancer Biol 2022;78:17– 22.
31. Geremia A, Arancibia-Carcamo CV. Innate lymphoid cells in intestinal inflammation. Front Immunol 2017;8:1296
32. Kvorjak M, Ahmed Y, Miller ML, Sriram R, Coronnello C, Hashash JG, et al. Cross-talk between colon cells and macrophages Increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer. Cancer Immunol Res 2020;8:167–78.
33. Posselt G, Crabtree JE, Wessler S. Proteolysis in Helicobacter pylori-Induced Gastric Cancer. Toxins 2017;9:134.
34. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 2014;345:196–202.
35. Gilligan GM, Panico RL, Di Tada C, Piemonte ED, Brunotto MN. Clinical and Immunohistochemical epithelial profile of nonhealing chronic traumatic ulcers. Med Oral Patol Oral Cir Bucal 2020;25:706–13.
36. Gajarawala SN, Pelkowski JN, Pettit PD, Lewis GK. Marjolin's Ulcer: Mesh-related vaginal cutaneous fistula with superimposed osteomyelitis and neoplastic transformation. Cureus 2021;13:e16476.
37. Wu JH, Lv CF, Guo XJ, Zhang H, Zhang J, Xu Y, et al. Low dose of emodin inhibits hypercholesterolemia in a rat model of high cholesterol. Med Sci Monit 2021;27:e929346.
38. Zacharias WJ, Frank DB, Zepp JA, Morley MP, Alkhaleel FA, Kong J, et al. Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 2018;555:251–5.
39. Liu L, Li H, Guo Z, Ma X, Cao N, Zheng Y, et al. The combination of three natural compounds effectively prevented lung carcinogenesis by optimal wound healing. PLoS One 2015;10:e0143438.
40. Du Z, Zhang S, Lin Y, Zhou L, Wang Y, Yan G, et al. Momordicoside G regulates macrophage phenotypes to stimulate efficient repair of lung injury and prevent urethane-induced lung carcinoma lesions. Front Pharmacol 2019;10:321.
41. Fishbein A, Hammock BD, Serhan CN, Panigrahy D. Carcinogenesis: Failure of resolution of inflammation? Pharmacol Ther 2021;218:107670.
42. Piotrowski I, Kulcenty K, Suchorska W. Interplay between inflammation and cancer. Rep Pract Oncol Radiother 2020;25:422–7.
43. Jiang N, Li Z, Luo Y, Jiang L, Zhang G, Yang Q, et al. Emodin ameliorates acute pancreatitis-induced lung injury by suppressing NLRP3 inflammasome-mediated neutrophil recruitment. Exp Ther Med 2021;22:857.
44. Liu Y, Shang L, Zhou J, Pan G, Zhou F, Yang S. Emodin at-tenuates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome-dependent pyroptosis signaling pathway in vitro and in vivo. Inflammation 2022;45:753–67.
45. Gao Z, Sui J, Fan R, Qu W, Dong X, Sun D. Emodin protects against acute pancreatitis-associated lung injury by inhibiting NLPR3 inflammasome activation via Nrf2/HO-1 signaling. Drug Des Devel Ther 2020;14:1971–82.
46. Guo R, Li Y, Han M, Liu J, Sun Y. Emodin attenuates acute lung injury in Cecal-ligation and puncture rats. Int Immunopharmacol 2020;85:106626
47. Tian SL, Yang Y, Liu XL, Xu QB. Emodin attenuates bleomycininduced pulmonary fibrosis via anti-inflammatory and antioxidative activities in rats. Med Sci Monit 2018;24:1–10 
48. Xu C, Zhang J, Liu J, Li Z, Liu Z, Luo Y, et al. Proteomic analysis reveals the protective effects of emodin on severe acute pancreatitis induced lung injury by inhibiting neutrophil proteases activity. J Proteomics 2020;220:103760.
49. Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021;137:1669–78.
50. Han JW, Shim DW, Shin WY, Heo KH, Kwak SB, Sim EJ, et al. Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation. Int J Mol Sci 2015;16:8102–9.
51. Xu Q, Wang M, Guo H, Liu H, Zhang G, Xu C, et al. Emodin alleviates severe acute pancreatitis-associated acute lung injury by inhibiting the cold-inducible RNA-binding protein (CIRP)- mediated activation of the NLRP3/IL-1β/CXCL1 signaling. Front Pharmacol 2021;12:655372.
52. Xiang H, Tao X, Xia S, Qu J, Song H, Liu J, et al. Emodin alleviates sodium taurocholate-induced pancreatic acinar cell injury via MicroRNA-30a-5p-mediated inhibition of high-temperature requirement a/transforming growth factor beta 1 inflammatory signaling. Front Immunol 2017;8:1488.
53. Song Y, Cui X, Zhao R, Hu L, Li Y, Liu C. Emodin protects against lipopolysaccharide-induced inflammatory injury in HaCaT cells through upregulation of miR-21. Artif Cells Nanomed Biotechnol 2019;47:2654–61.
54. Jiang J, Zhou N, Ying P, Zhang T, Liang R, Jiang X. Emodin promotes apoptosis of human endometrial cancer through regulating the MAPK and PI3K/ AKT pathways. Open Life Sci 2018;13:489–96.
55. Leiva O, Newcomb R, Connors JM, Al-Samkari H. Cancer and thrombosis: new insights to an old problem. J Med Vasc 2020;45:6S8–6S16.
56. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137:1959–69.
57. Di W, Xu H, Xue T, Ling C. Advances in the prediction and risk assessment of lung cancer-associated venous thromboembolism. Cancer Manag Res 2021;13:8317–27. 
58. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev 2017;36:199–213.
59. Prandoni P, Campello E. Venous thromboembolism in cancer patients undergoing chemotherapy: risk factors and prevention. Semin Thromb Hemost 2021;47:914–9. 
60. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835–46.
61. Campello E, Ilich A, Simioni P, Key NS. The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. Br J Cancer 2019;121:359–71.
62. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet 2021;398:64–77. 
63. O'Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. Oncologist 2021;26:e8–e16.
64. Pedersen S, Kristensen AF, Falkmer U, Christiansen G, Kristensen SR. Increased activity of procoagulant factors in patients with small cell lung cancer. PLoS One 2021;16:e0253613. 
65. Yan AR, Samarawickrema I, Naunton M, Peterson GM, Yip D, De Rosa S, et al. Risk factors and prediction models for venous thromboembolism in ambulatory patients with lung cancer. Healthcare (Basel) 2021;9:778.
66. Schmaier AA, Ambesh P, Campia U. Venous thromboembolism and cancer. Curr Cardiol Rep 2018;20:89
67. Abreu SC, Tavares V, Carneiro F, Medeiros R. Venous thromboembolism and prostate cancer: what about genetic markers? Pharmacogenomics 2021;22:365–73. 
68. Qian X, Fu M, Zheng J, Zhou J, Zhou J. Driver genes associated with the incidence of venous thromboembolism in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Front Oncol 2021;11:680191.
69. Kenmotsu H, Notsu A, Mori K, Omori S, Tsushima T, Satake Y, et al. Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study. Cancer Med 2021;10:895–904.
70. Zhou J, Song Z, Han M, Yu B, Lv G, Han N, et al. Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis. Biomed Pharmacother 2018;97:1622–31.
71. Gao D, Wu SN, Zhang CE, Li RS, Liu ZJ, Xiao XH, et al. Exploration in the mechanism of rhubarb for the treatment of hyperviscosity syndrome based on network pharmacology. J Ethnopharmacol 2020;261:113078.
72. Luo N, Fang J, Wei L, Sahebkar A, Little PJ, Xu S, et al. Emodin in atherosclerosis prevention: Pharmacological actions and therapeutic potential. Eur J Pharmacol 2021;890:173617. 
73. Li Q, Gao J, Pang X, Chen A, Wang Y. Molecular mechanisms of action of emodin: as an anti-cardiovascular disease drug. Front Pharmacol 2020;11:559607.
74. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938–49.
75. Nemmar A, Dhaheri RA, Alamiri J, Hefeiti SA, Saedi HA, Beegam S, et al. Diesel exhaust particles induce impairment of vascular and cardiac homeostasis in mice: ameliorative effect of emodin. Cell Physiol Biochem 2015;36:1517–26.
76. Li Z, Lin Y, Zhang S, Zhou L, Yan G, Wang Y, et al. Emodin regulates neutrophil phenotypes to prevent hypercoagulation and lung carcinogenesis. J Transl Med 2019;17:90.
77. Bertin FR, Lemarié CA, Robins RS, Blostein MD. Growth arrestspecific 6 regulates thrombin-induced expression of vascular cell adhesion molecule-1 through forkhead box O1 in endothelial cells. J Thromb Haemost 2015;13:2260–72.
78. Xie W, Zhang L, Luo W, Zhai Z, Wang C, Shen YH. AKT2 regulates endothelial-mediated coagulation homeostasis and promotes intrathrombotic recanalization and thrombus resolution in a mouse model of venous thrombosis. J Thromb Thrombolysis 2020;50:98–111.
79. Zhu T, Zhang W, Feng SJ, Yu HP. Emodin suppresses LPSinduced inflammation in RAW264.7 cells through a PPARγdependent pathway. Int Immunopharmacol 2016;34:16–24. 
80. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett 2017;387:61–8. 
81. Li Z, Feiyue Z, Gaofeng L. Traditional Chinese medicine and lung cancer--From theory to practice. Biomed Pharmacother 2021;137:111381.
82. Cui B, Peng F, Lu J, He B, Su Q, Luo H, et al. Cancer and stress: NextGen strategies. Brain Behav Immun 2021;93:368–83.
83. Su XL, Wang JW, Che H, Wang CF, Jiang H, Lei X, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer. Chin Med J (Engl) 2020;133:2987– 97.
84. Wang S, Long S, Wu W. Application of traditional Chinese medicines as personalized therapy in human cancers. Am J Chin Med 2018;46:953–70.
85. Zeng JY, Wang Y, Miao M, Bao XR. The effects of rhubarb for the treatment of diabetic nephropathy in animals: a systematic review and meta-analysis. Front Pharmacol 2021;12:602816.
86. Zhang Q, Liu J, Li R, Zhao R, Zhang M, Wei S, et al. A network pharmacology approach to investigate the anticancer mechanism and potential active ingredients of rheum palmatum L. Against Lung Cancer via Induction of Apoptosis. Front Pharmacol 2020;11:528308.
87. Zheng YF, Liu CF, Lai WF, Xiang Q, Li ZF, Wang H, et al. The laxative effect of emodin is attributable to increased aquaporin 3 expression in the colon of mice and HT-29 cells. Fitoterapia 2014;96:25–32.
88. Zhang HQ, Zhou CH, Wu YQ. Effect of emodin on small intestinal peristalsis of mice and relevant mechanism. World J Gastroenterol 2005;11:3147–50.
89. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev 2007;27:591–608.
90. Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, et al. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/
neu-induced cellular transformation and metastasis-associated properties. Oncogene 1998;16:2855–63.
91. Zeng YQ, Dai Z, Lu F, Lu Z, Liu X, Chen C, et al. Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease. Oncotarget 2016;7:17468–78.
92. Chen D, Liu J, Lu L, Huang Y, Wang Y, Wang M, et al. Emodin attenuates TNF-α-induced apoptosis and autophagy in mouse C2C12 myoblasts though the phosphorylation of Akt. Int Immunopharmacol 2016;34:107–13.
93. Zou G, Zhang X, Wang L, Li X, Xie T, Zhao J, et al. Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics 2020;10:6839–53.
94. Fleur LL, Botling J, He F, Pelicano C, Zhou C, He C, et al. Targeting MARCO, IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Res 2021;81:956–67.
95. Brozos-Vazquez EM, Diaz-Pena R, Garcia-Gonzalez J, Leon-Mateos L, Mondelo-Macia P, Pena-Chilet M, et al. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunol Immunother 2021;70:1177–88.
96. Sangaletti S, Ferrara R, Tripodo C, Garassino MC, Colombo MP. Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunol Immunother 2021;70:2429– 38.
97. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology 2016;21:821–33.
98. Wang S, Long S, Deng Z, Wu W. Positive role of Chinese herbal medicine in cancer immune regulation. Am J Chin Med 2020;48:1577–92.
99. Wang Y, Zhang Q, Chen Y, Liang CL, Liu H, Qiu F, et al. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother 2020;121:109570.
100. Harikrishnan R, Jawahar S, Thamizharasan S, Paray BA, AlSadoon MK, Balasundaram C. Immune defense of emodin enriched diet in Clarias batrachus against Aeromonas hydrophila. Fish Shellfish Immunol 2018;76:13–20.
101. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anticancer therapy. Adv Drug Deliv Rev 2016;99:180–5.
102. Hwang I, Kim JW, Ylaya K, Chung EJ, Kitano H, Perry C, et al. Tumor-associated macrophage, angiogenesis and lymphan- giogenesis markers predict prognosis of non-small cell lung cancer patients. J Transl Med 2020;18:443.
103. Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab 2019;30:36–50.
104. Iwanowycz S, Wang J, Altomare D, Hui Y, Fan D. Emodin bidirectionally modulates macrophage polarization and epigenetically regulates macrophage memory. J Biol Chem 2016;291:11491–503.
105. Iwanowycz S, Wang J, Hodge J, Wang Y, Yu F, Fan D. Emodin inhibits breast cancer growth by blocking the tumor-promoting feedforward loop between cancer cells and macrophages. Mol Cancer Ther 2016;15:1931–42.
106. Kim YJ, Lee JY, Kim HJ, Kim DH, Lee TH, Kang MS, et al. Inhibitory effect of emodin on raw 264.7 activated with double stranded RNA analogue poly I:C. Afr J Tradit Complement Altern Med 2017;14:157–66.
107. Jia X, Yu F, Wang J, Iwanowycz S, Saaoud F, Wang Y, et al. Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res Treat 2014;148:291–302.
108. Song YD, Li XZ, Wu YX, Shen Y, Liu FF, Gao PP, et al. Emodin alleviates alternatively activated macrophage and asthmatic airway inflammation in a murine asthma model. Acta Pharmacol Sin 2018;39:1317–25.
109. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res 2019;79:4557–66.
110. Sharma R, Tiku AB. Emodin inhibits splenocyte proliferation and inflammation by modulating cytokine responses in a mouse model system. J Immunotoxicol 2016;13:20–6.
111. Hua S, Liu F, Wang M. Emodin alleviates the airway inflammation of cough variant asthma in mice by regulating the notch pathway. Med Sci Monit 2019;25:5621–9.
112. Wang J, Zhang Y, Zhu Q, Liu Y, Cheng H, Zhang Y, et al. Emodin protects mice against radiation-induced mortality and intestinal injury via inhibition of apoptosis and modulation of p53. Environ Toxicol Pharmacol 2016;46:311–8.
113. Zhang FY, Li RZ, Xu C, Fan XX, Li JX, Meng WY, et al. Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa. Phytomedicine 2022;95:153786.
114. Ying Y, Qingwu L, Mingming X, Zhenju S, Chaoyang T, Zhengang T. Emodin: One main ingredient of Shufeng Jiedu capsule reverses chemoresistance of lung cancer cells through inhibition of EMT. Cell Physiol Biochem 2017;42:1063–72.
115. Wang X, Li L, Guan R, Zhu D, Song N, Shen L. Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells. Cell Physiol Biochem 2017;44:1337–51.
116. Ok S, Kim SM, Kim C, Nam D, Shim BS, Kim SH, et al. Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4. Immunopharmacol Immunotoxicol 2012;34:768– 78
117. Chen S, Zhang Z, Zhang J. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo. Drug Des Devel Ther 2019;13:1145–53.
118. He L, Bi JJ, Guo Q, Yu Y, Ye XF. Effects of emodin extracted from Chinese herbs on proliferation of non-small cell lung cancer and underlying mechanisms. Asian Pac J Cancer Prev 2012;13:1505–10.
119. Su YT, Chang HL, Shyue SK, Hsu SL. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol 2005;70:229–41.
120. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, et al. Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 2010;79:655–64
121. Lai JM, Chang JT, Wen CL, Hsu SL. Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells. Eur J Pharmacol 2009;623:1–9
122. Li M, Jin S, Cao Y, Xu J, Zhu S, Li Z. Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acidmediated motility (RHAMM) interaction-dependent signaling pathway. Cancer Cell Int 2021;21:19.
123. Li WY, Ng YF, Zhang H, Guo ZD, Guo DJ, Kwan YW, et al. Emodin elicits cytotoxicity in human lung adenocarcinoma A549 cells through inducing apoptosis. Inflammopharmacology 2014;22:127–34.
124. Lu SY, Chen JJ, Pan JI, Fu ZX, Wu JL, Hsieh TC. The association between different patterns of traditional Chinese medicine treatment and all-cause mortality among cancer patients. Integr Cancer Ther 2019;18:1534735418823273.
125. Xiang Y, Guo Z, Zhu P, Chen J, Huang Y. Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science. Cancer Med 2019;8:1958–75.
126. Stompor-Goracy M. The health benefits of emodin, a natural anthraquinone derived from rhubarb-A summary update. Int J Mol Sci 2021;22:9522.
127. Lee EH, Baek SY, Park JY, Kim YW. Emodin in Rheum undulatum inhibits oxidative stress in the liver via AMPK with Hippo/ Yap signalling pathway. Pharm Biol 2020;58:333–41.
128. Xiao D, Zhang Y, Wang R, Fu Y, Zhou T, Diao H, et al. Emodin alleviates cardiac fibrosis by suppressing activation of cardiac fibroblasts via upregulating metastasis associated protein 3. Acta Pharm Sin B 2019;9:724–33.
129. Chen Y, Zhang T, Wu L, Huang Y, Mao Z, Zhan Z, et al. Me- tabolism, toxicity of emodin: genome-wide association studies reveal hepatocyte nuclear factor 4alpha regulates UGT2B7 and emodin glucuronidation. Chem Res Toxicol 2020;33:1798–808. 
130. Jiang LL, Jiang Y, Zhao DS, Fan YX, Yu Q, Li P, et al. CYP3A Activation and glutathione depletion aggravate emodin-induced liver injury. Chem Res Toxicol 2018;31:1052–60. 
131. Dong X, Fu J, Yin X, Cao S, Li X, Lin L, et al. Emodin: A Review of its pharmacology, toxicity and pharmacokinetics. Phytother Res 2016;30:1207–18.
132. Zhang Y, Pu W, Bousquenaud M, Cattin S, Zaric J, Sun LK, et al. Emodin inhibits inflammation, carcinogenesis, and cancer progression in the AOM/DSS model of colitis-associated intestinal tumorigenesis. Front Oncol 2020;10:564674.
133. Gao R, Wang C, Han A, Tian Y, Ren S, Lv W, et al. Emodin improves intestinal health and immunity through modulation of gut microbiota in mice infected by pathogenic escherichia coli O1. Animals (Basel) 2021;11:3314.